Ternary Health
Apply
Ternary Health
A Ternary Intelligence service
DOC · TH-PD-M073
CONFIDENTIAL
04 · 2026
Precision Deep Dive · Personalized Action Plan

Mast Cell Activation Syndrome action plan

A personalized synthesis for a premenopausal non-clonal MCAS case with Hereditary Alpha Tryptasemia (TPSAB1 triplication), triple-pathway mediator activation, the full MCAS-hEDS-POTS trifecta, and an active pre-conception decision window.

Prepared for
Sample · H.R., 34
Condition
Non-clonal MCAS · HαT-plus
Pages
55
Lead reviewers
Giannini · Paramonov
Contents
  1. 01Executive summary
  2. 02Case synthesis
  3. 03Disease model — your version
  4. 04Specialist pathway
  5. 05Clinical workup and biomarkers
  6. 06Signal analysis — your activation map
  7. 07Genetic findings — variant-level review
  8. 08Mast cell biomarker analysis
  9. 09Intervention prioritization — Ternary Method applied
  10. 10Medical therapy — discussion points
  11. 11Supplement framework
  12. 12Trigger mapping, diet, and movement
  13. 13Sleep, recovery, and supportive care
  14. 14Monitoring plan
  15. 1590-day execution blueprint
  16. 16Questions for your physicians
  17. 17Resources and communities
Section 01

Executive summary

What this plan says and the three moves that matter most in the next 30 days.

Client in one paragraph

A 34-year-old premenopausal woman of Ashkenazi Jewish and Northern European ancestry with a 14-year history of progressively worsening multi-system allergic-type symptoms. Diagnosed non-clonal Mast Cell Activation Syndrome (Vienna consensus criteria) in September 2024 at Brigham & Women’s Mastocytosis Center after nine years cycling through “chronic idiopathic urticaria,” IBS, anxiety disorder, food allergy, and POTS diagnoses. Confirmed TPSAB1 triplication (3α alleles), documented 20%+2 tryptase rise, triple-pathway urinary mediator elevation, the full MCAS-hEDS-POTS trifecta, and four EpiPen-requiring events in the last 12 months on baseline triple therapy. Pre-conception decisions active within 12–18 months.

01
Escalate the mast cell regimen in a structured, evidence-driven sequence. Current cetirizine 10 mg BID + famotidine 20 mg BID + montelukast 10 mg is baseline but insufficient for your flare burden (3.2 flares/week, 6/10 severity). The Castells/Afrin consensus escalation adds a mast cell stabilizer (oral cromolyn 100–200 mg QID or ketotifen), low-dose aspirin (elevated 11β-PGF2α is the exact biomarker indication), and omalizumab 300 mg SC q4wk for persistent anaphylactoid episodes. Each layer requires 6–8 weeks of isolation before the next is added.
02
Map your personal trigger graph rigorously in the next 60 days. MCAS treatment is 50% pharmacology and 50% trigger avoidance. Flare diary shows clustering around cycle days 24–28, gluten or alcohol exposure, heat, and sleep debt. What is not mapped: food histamine load, fragrance/cleaning chemicals, medication cofactors (NSAIDs, opioids, contrast), and physical triggers. 60 days of structured Bearable diary + low-histamine baseline + CGM-paired meal testing separates probabilistic triggers from coincidence.
03
Address the hEDS + POTS comorbidity stack in parallel, not sequentially. The trifecta amplifies predictably: POTS adrenergic drive triggers mast cells; hEDS tissue fragility increases mechanical mast cell exposure; MCAS vascular permeability worsens POTS. You have formal diagnoses of all three but only MCAS is being actively treated. POTS compression + salt/fluid loading + mast-cell-safe β-blocker (ivabradine or propranolol) and hEDS-specific PT (Muldowney protocol) should be layered alongside MCAS treatment, not deferred to month three.
04
Correct the pre-conception nutrient stack and plan the pregnancy-MCAS coordination. Ferritin 18, vitamin D 21, functional B12 insufficiency (B12 318 + MMA elevated), zinc 68, homocysteine 11.4 — all below pre-conception targets. IV iron (ferric carboxymaltose) is preferred over oral in MCAS given GI trigger risk. An MFM + Brigham coordinated pre-conception consult is the sequencing call to make around week 8–12, once the medication regimen is stable enough to commit to a pregnancy-compatible baseline.
The honest framing
MCAS is not curable with current medicine. The underlying mast cell hyperreactivity — amplified in your case by the TPSAB1 triplication you cannot change — will persist. No FDA-approved treatment exists specifically for MCAS; every effective intervention is off-label, borrowed from mastocytosis protocols, or drawn from case-series evidence. What canchange: flare frequency (realistic goal 3.2/week → <1/week), flare severity (6/10 → ≤3/10), anaphylactoid events (4/year → <1/year), and tolerated food count (~40 → ~100–120). The goal is a durable symptom floor you can live on, with a clear decision tree for escalation when life events (pregnancy, surgery, travel) require it.
Section 02

Case synthesis

Timeline, clinical picture, and stated goals reconstructed into one coherent narrative.

Clinical timeline

YearEvent
~2003 – 2005Onset age 11–12: recurrent unexplained urticaria. Treated with episodic diphenhydramine; dismissed as childhood allergy.
2006 – 2013Migraines (age 14+), IBS diagnosis at 19, college 'panic attacks' with flushing/tachycardia/near-syncope (age 20–22). Multi-food 'allergic reactions' with no consistent trigger.
2015Diagnosed chronic idiopathic urticaria. Began continuous cetirizine.
2017 – 2018IBS-D diagnosis; generalized anxiety diagnosis — the latter a mischaracterization of physical events.
2022Physical therapist first to suspect hEDS based on joint hypermobility. Stopped drinking alcohol after repeated flares.
Apr 2023hEDS formally confirmed (Beighton 7/9) at EDS Clinic of Austin. Tilt-table confirms POTS (HR rise 42 bpm). Rheumatology triggers Brigham referral.
Sep 2024Brigham diagnoses non-clonal MCAS after documented 20%+2 tryptase rise during Nov 2024 flare (18.6 → 27.4 ng/mL). TPSAB1 triplication confirmed Oct 2024 — HαT-plus phenotype.
2025 – 2026On cetirizine + famotidine + montelukast; 3.2 flares/week, 4 EpiPen events in 12 months. Weight 140 &rarr; 128 lb over 18 months from restriction + GI symptoms. Active pregnancy discussion.

Stated goals (kickoff call, January 24, 2026)

  • “I want to stop having ER visits. Four EpiPens last year is too many.”
  • “I want to eat more than 40 foods without anxiety.”
  • “I want to go back to hot yoga without triggering a flare.”
  • “I want to know if I can safely get pregnant, and if so when to start.”
  • “I want to understand which of my triggers are real and which are just fear.”

Current medications & prior therapy trials

Cetirizine 10 mg BID (~4 years), famotidine 20 mg BID (~2 years), montelukast 10 mg HS (~18 months), EpiPen 0.3 mg ×2 carried at all times, propranolol 10 mg PRN for tachycardia (~6 months), magnesium glycinate 400 mg HS. Prior trials: diphenhydramine (rescue only — works but sedating), hydroxyzine (brief 2023, too sedating), fexofenadine (2024, less effective than cetirizine), fish oil (ongoing), quercetin (self-trial, possible modest benefit), DAO supplement with meals (ambiguous), CBT for health anxiety (2022–2023, helpful). Has never trialed cromolyn, ketotifen, omalizumab, or low-dose aspirin — i.e., the entire published escalation ladder is still available.

Section 03

Disease model — your version

Four upstream drivers feed the downstream MCAS flare phenotype. Three of four are actionable.

Evidence-weighted driver model for this case
Hereditary tryptase dosage (TPSAB1 triplication / HαT)
High · non-modifiable
Reduced histamine degradation capacity (DAO / HNMT / MAO / MTHFR)
High · partially modifiable
Autonomic-mechanical co-activation (POTS + hEDS trifecta)
High · modifiable
Trigger exposure load (food histamine, chemicals, heat, hormonal)
High · highly modifiable
Pro-inflammatory substrate (baseline mediator drive)
Moderate · partially modifiable

Your case is a well-documented non-clonal MCAS with HαT-plus phenotype — meaning the hereditary tryptase trait is almost certainly contributing to the clinical syndrome, not merely coincident. Three convergent diagnostic legs (TPSAB1 triplication + documented tryptase dynamic + triple-pathway urinary mediator elevation) place you in the most well-characterized, most treatable subtype of MCAS. What is distinctive is the extent of pharmacogenomic amplification: the DAO–HNMT–MAO–MTHFR cluster means your histamine-clearance machinery is throttled at multiple steps, which explains why standard H1 dosing has been insufficient.

What that means practically

  • Sequencing discipline is the treatment. MCAS has a relatively clear escalation ladder. The challenge is not what to try but trying each layer long enough (6–8 weeks) to evaluate its contribution before stacking the next.
  • Standard H1 doses are probably sub-therapeutic for you. Castells/Afrin MCAS practice routinely uses 2–4× FDA doses in HαT patients. Your genetic throttle argues for escalation, not substitution.
  • The trifecta stack runs in parallel. Treating MCAS alone under-performs predictably when POTS and hEDS are active and untreated — each amplifies the others.
  • KIT D816V negative keeps oncologic differentials closed. No systemic mastocytosis, no clonal workup, no steroid burst as chronic strategy. The plan is MCAS optimization, not mastocytosis management.
Preview ends here — 14 more sections follow.

See this depth applied to your condition.

This is a sample built on a composite case — we don’t publish the full sample. A Ternary Brief on your own situation is free and takes about three minutes.

You’re reading 3 of 17 sections. The full Precision Deep Dive continues with specialist pathway, clinical workup and biomarkers, signal analysis, genetic findings, and more.

Get your free Ternary BriefApply for a Case Review

Educational sample on a composite case. Your brief and any report are built from your own situation and are never shared.

Ternary Health
A Ternary Intelligence service · San Francisco
Precision Deep Dive · Sample · © 2026